A PILOT STUDY OF AN ENDOLUMINAL-SUTURING DEVICE AS A TREATMENT FOR PATIENTS WITH GASTRO ESOPHAGEAL REFLUX DISEASE

Hubert Louis, Pauline Van Ouytsel, Loulia Leclercq, Mélina Houinsou Hans, Jacques Devière, Ricardo Rio-Tinto, Vincent Huberty.

Affiliations below.

DOI: 10.1055/a-2185-5947

Please cite this article as: Louis H, Van Ouytsel P, Leclercq L et al. A PILOT STUDY OF AN ENDOLUMINAL-SUTURING DEVICE AS A TREATMENT FOR PATIENTS WITH GASTRO ESOPHAGEAL REFLUX DISEASE. Endoscopy International Open 2023. doi: 10.1055/a-2185-5947

Conflict of Interest: Endo Tools Therapeutics S.A. (Gosselies, Belgium) provided a grant covering medical devices and data management. Drs. Huberty and Deviere are shareholders in Endo Tools SA, which was initially a startup of the Université Libre de Bruxelles where they have appointments.

Endo Tools Therapeutics S.A. (Gosselies, Belgium) provided a grant covering medical devices and data management. Drs. Huberty and Deviere are shareholders in Endo Tools Therapeutics S.A., which is a spin-off of the Université libre de Bruxelles. Loulia Leclercq is employee at Endo Tools Therapeutics S.A. Hubert Louis, Pauline Van Ouytsel, Mélina Houinsou Hans, and Ricardo Rio Tinto have no competing interest.

Trial registration: NCT03999502, ClinicalTrials.gov (http://www.clinicaltrials.gov/), Prospective

Abstract:
Background and study aims Endoscopic therapy is a promising option for patients with GERD. The aim of this study was to assess safety and feasibility of endomina suturing platform as a treatment for GERD.

Patients and methods This was a two-centre study on patients with chronic GERD symptoms responding at least partially to proton pump inhibitors (PPI). Primary endpoints were to assess safety of the procedure and persistence of the sutures. Secondary endpoints were to assess esophageal pH-impedance and manometry parameters changes at 6 months, as well as GERD symptoms and PPI use up to 12 months of follow-up.

Results Fourteen patients were treated (13 males, mean of 43 ± 12 years), with a mean number of 3 plications per patient. Thirteen, 10 and 9 patients were analysed at 3, 6 and 12 months of follow-up, respectively. One device-related adverse event occurred (loss of needle tip requiring endoscopic retrieval one week later). A mean number of 2 plications persisted at 3 and 12 months. A decrease in median acid exposure time and reflux episodes was observed after the procedure. Mean RSI and GERD-HRQL scores decreased during follow-up visits and 90% of the patients discontinued PPI use at 1 year.

Conclusion Endoscopic full-thickness suturing of the EGJ with the endomina suturing platform is feasible, allowing persistence of two thirds of the plications, with promising results to decrease reflux and improve GERD symptoms.

Corresponding Author:
Dr. Vincent Huberty, Erasme Hospital, Gastroenterology, Hepatopancreatology and GI oncology, route de lennik 808, 1070 brussels, Belgium, vincent.huberty@hubruxelles.be, vincent.huberty@hubruxelles.be

Affiliations:
Hubert Louis, Erasme Hospital, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Pauline Van Ouytsel, Erasme University Hospital, Gastroenterology, Hepatopancreatology and Digestive Oncology, Bruxelles, Belgium
Loulia Leclercq, EndoTools Therapeutics, Gastroenterology, Gosselies, Belgium

[...]

Vincent Huberty, Erasme Hospital, Gastroenterology, Hepatopancreatology and GI oncology, Brussels, Belgium
1. INTRODUCTION

Gastroesophageal Reflux Disease (GERD) is a common problem affecting 10-20% of the population in the Western World [1]. Proton pump inhibitors (PPIs) heal esophagitis and improve GERD symptoms in many patients. However, acid suppressive therapy does not correct the underlying pathophysiology of esophagogastric junction (EGJ) dysfunction in GERD, and hence symptoms of reflux due to weakly acidic or non-acid reflux persist in a significant of patients with GERD [2, 3]. Laparoscopic antireflux surgery restores the EGJ barrier function against reflux of the gastric content, is effective in reducing both reflux and GERD symptoms and is a therapeutic option in patients with severe GERD, with persisting symptoms due to reflux, or unwilling to take PPIs [4, 5]. However, concerns remain regarding postoperative adverse events and durability of the surgical procedure [6, 7]. For these reasons, minimally-invasive endoscopic techniques have been developed during the last 2 decades [8, 9, 10].

Endoma v2 is a CE-marked device that can be attached to an endoscope inside the body, allowing manipulation of angulated tools during a peroral intervention and offering the possibility to perform transoral surgical full thickness sutures. Transoral endoscopic gastroplasty has shown to be safe and effective at mid-term follow-up in obese patients using endoma device [11, 12]. The ability to perform endoscopic full-thickness plications with endoma v2 was therefore used in a pilot study to assess safety and feasibility of the procedure in patients with persistent GERD symptoms despite daily PPI use.
2. PATIENTS AND METHODS

2.1. Study design and objective

This was a two-centre, prospective open-label pilot study that was designed to evaluate the feasibility and the safety of the endomina suturing platform as a treatment for GERD in subjects with chronic GERD symptoms responding at least partially to PPIs, requiring daily PPI use, and who continued to have symptoms despite maximal medical therapy. During a screening period, upper GI endoscopy (if not performed within the last 12 months), high resolution oesophageal manometry and ambulatory oesophageal pH-impedance monitoring were performed. Twenty-four-hour ambulatory esophageal pH-impedance monitoring was performed using a multi-channel intraluminal impedance system (Diversatek, CO, USA). The combined pH-impedance catheter was placed transnasally, with the pH-electrode positioned 5 cm above the upper border of the manometrically defined EGJ, and the impedance segments positioned 3, 5, 7, 9, 15, and 17 cm above the proximal border of the EGJ. The use of PPIs was discontinued 7 days before. Automated analysis of the pH-impedance study was performed, followed by a manual review of the tracing.

GERD HRQL and Reflux Symptom Index questionnaires were completed by the patients. Eligible patients were given clear information about the endoscopic procedure and the assessments required by the study, and gave their informed consent. Follow-up visits were scheduled at 1, 3, 6 and 12 months after the procedure for safety, symptoms, quality of life and PPI use assessment. Upper GI endoscopy was performed at 3 and 12 months, and high-resolution oesophageal manometry and ambulatory oesophageal pH-impedance monitoring at 6 months.

The study was approved by the local Ethics committees and was registered in ClinicalTrials.gov (Identifier: NCT03999502).

2.2. Patients

Inclusion criteria were as follows: adult patients aged 21-70 with chronic symptoms of GERD (heartburn and/or regurgitations for longer than 12 months), under daily PPI therapy for at least 6
months and responding at least partially to PPIs (worse heartburn and/or regurgitations when patients stopped taking their PPI), with documented GERD [defined with at least two of the following criteria: a previous demonstration of reflux esophagitis grade A, B or C (Los Angeles classification), an acid exposure time > 4% during esophageal pH-impedance monitoring performed after at least 7 days off PPIs, a positive association between GERD symptoms and reflux episodes (symptom association probability ≥ 95%)].

Exclusion criteria comprised a previous esophageal or gastric laparoscopic or endoluminal surgery, a hiatal hernia greater than 3 cm, Barret’s esophagus, history of grade D esophagitis, gastroparesis diagnosed by gastric emptying scintigraphy in case of symptoms compatible with gastroparesis and after exclusion of a mechanical obstruction, a major esophageal motility disorder, esophageal or gastric varices, a history of malignancy, a BMI > 35 kg/m², and type I or uncontrolled type II diabetes.

2.3. Endoluminal procedure and postoperative course

The endomina v2 is a triangulation platform used with a flexible endoscope and a dedicated needle (TAPES, Endo Tools Therapeutics SA, Gosselies, Belgium) to create gastrointestinal sutures. The devices are currently CE-marked for endoscopic gastroplasty and were used in this study as a pre-market indication, i.e., the treatment of GERD. In the endomina family, there are two platforms that were used in this study: the endomina v2 and the endomina v2-mini. The endomina v2 has a therapeutic channel that can be bent perpendicularly to the axis of vision allowing piercing under visual control. The endomina v2-mini has a pre-angled therapeutic channel allowing tissue appositions in narrower spaces, e.g., the esophagus.

The platform is inserted over one rigid guidewire into the stomach and can then be opened and tightened around the endoscope. This feature obviates the need to use an overtube and allows the endoscopist to assemble/detach the system when needed without having to withdraw the device. The endomina comprises additional channel(s) that can be used for instrument insertion or flushing, leaving the endoscope channel free for instrumentation.
Grasping forceps were used through the endoscope channel to pull the gastric tissue inside the endomina platform, and a dedicated needle (TAPES) was then used for tissue piercing. Each TAPES was loaded with two anchors connected by surgical suture, allowing creation of single or double plications (interrupted stitches). The anchors were then pulled towards each other using a snare until the formation of a tight serosa-to-serosa apposition.

Sutures were placed in retroflexion at the esophagogastric junction (EGJ). Two to four sutures (depending on the space available in retroflexion) were placed in a step by step approach from the gastric fundus to the esophageal lumen over 240 degrees (leaving the smaller curvature intact) (Figure 1). This generated a narrowing of the EGJ and a "bump" in the gastric fundus distal to the EGJ. Procedures were done using the endomina v2 and the endomina v2-mini at the operator’s discretion. All procedures were performed under general anesthesia with orotracheal intubation. Patients were kept overnight per protocol. Patients received antispasmodic and antiemetic drugs for ten days and were asked to continue on their daily proton pump inhibitor (PPI) for three months. They were kept on a liquid diet for three days after the procedure and then returned to solid food within ten days.

2.4. Study endpoints

Primary endpoints of the study were feasibility defined as persistence of sutures at endoscopy at 3 and 12 months of follow-up, and safety characterized by the incidence of adverse device effects assessed at each follow-up visit, according to the Clavien-Dindo classification.

Secondary endpoints were as following: change from baseline to 6 months esophageal acid exposure time (AET), number of distal and proximal reflux episodes, DeMeester score, lower esophageal sphincter (LES) pressure, and the 4-second integrated relaxation pressure (IRP4s) of LES pressure (IRP4s); change from baseline of PPI use at 6- and 12-months follow-up; change from baseline to the 3-, 6- and 12-months follow-up visit of the mean RSI and GERD-HRQL scores (it appeared afterwards that questions 10 to 14 of the GERD-HRQL were not available for the Portuguese patients).
2.5. Statistical analysis

We planned to enrol 15 patients in this pilot study. Descriptive analysis was performed using mean and standard variation (SD) or median and IQR depending normality of the data for numeric parameters. Count and percentages were presented in each category of the categorical variables.

In order to evaluate the change between times of esophageal acid exposure time (AET), number of distal and proximal reflux episodes, DeMeester score, lower esophageal sphincter (LES) pressure, and the 4-second integrated relaxation pressure (IRP4s) of LES pressure (IRP4s), medians of delta (difference between baseline and 6 months follow-up) with Confidence intervals at 95% were calculated with SAS Enterprise guide 8.3.

3. Results

From September 2018 to December 2021, 17 patients with GERD were enrolled (Figure 2). General characteristics of the patients are given in Table 1. Patients were on chronic daily PPI treatment [15 to 80 mg per day, mean duration 8.5 years, esomeprazole (5 patients), lansoprazole (3 patients), omeprazole (3 patients), pantoprazole (2 patients) and rabeprazole (1 patient)].

All patients had their heartburn score worsened 7 days after stopping PPI and had persistent regurgitations under PPI. Three patients had no esophagitis under PPI treatment, eleven patients had esophagitis (7 grade A, 3 grade B and 2 grade C). Eight of the 14 patients had an AET > 6%, five patients with an AET<6% had a SAP>95% as a marker of GERD.

Three patients were considered enrolment failures: one patient with Barrett’s esophagus, one patient with a previous Nissen fundoplication and one patient with gastric food retention at endoscopy, due to non-Previously diagnosed gastroparesis. Fourteen patients were treated with the endoluminal procedure (8 in Brussels and 6 in Lisbon). Five patients were lost to follow up after 3 or 6
months, among whom 2 patients who later opted for a surgical fundoplication. Two patients missed their 3- or 6-months follow-up, respectively, but completed the other follow-up visits. All procedures were performed by experienced endoscopists (VH, JD and RRT) with a technical success rate of 100%. Mean procedure time was 01H07 ± 00H13. Five patients had 4 sutures performed, three patients 3 sutures and six patients 2 sutures. Eight of 14 patients (57%) complained of transient mild epigastric pain and/or dyspeptic symptoms (early satiety, belching) post procedure, that did not require medication and resolved within 4 weeks.

3.1 Primary endpoints

One adverse event related to the suturing procedure was recorded in one patient (graded 3b according to the Clavien Dindo classification), as the tip of one TAPES detached from the device and required endoscopic retrieval one week later. Corrective actions were thereafter implemented on the device and no recurrence was reported for subsequent patients. No adverse event was recorded during follow-up visits.

Persistence of the sutures was evaluated at endoscopy 3 and 12 months after the treatment. A mean number of 2 plications persisted at 3 and 12 months, compared to a mean number of 3 plications performed during the treatment procedure (Table 2). At 3-month follow-up, six patients had all sutures remaining, four patients had 1 suture lost and three patients had 2 sutures lost. At 12-month follow-up, six patients had all sutures remaining, one patient had 1 suture lost and two patients had 2 sutures lost.

3.2 Secondary endpoints

Analysis of reflux parameters showed that mean oesophageal acid exposure, DeMeester score, distal and proximal number of reflux episodes were all reduced 6 months after the endomina procedure.
Among the eight patients with an abnormal AET before the procedure, three normalized their AET, while two did not.

As a marker of LES augmentation, an increase in basal LES pressure as well as IRP4s, was observed at 6 months.

Concerning GERD symptoms, Mean RSI and GERD-HRQL scores decreased during follow up visits. PPI could be stopped after 3 months in most of the followed patients: only one out of the 9 patients followed at 12 months was still on a low dose of PPI.

Interestingly, although evaluation of esophagitis was not included as an endpoint in the study, endoscopic evaluation of patients at 1-year follow-up did not show esophagitis in most of the patients. Whereas Los Angeles esophagitis grade A, B or C was observed before endomina procedure in 7, 3 and 2 of the 14 patients, respectively, only 2 of the 9 patients followed at 12 months had grade A esophagitis and no reflux esophagitis was observed in the 7 other patients.

4. DISCUSSION

We report the results of a pilot study evaluating the endomina procedure as a treatment for patients with chronic GERD symptoms that persist under a daily PPI therapy. First, the study showed that endomina v2 device is a safe procedure that allowed making sutures under the EGJ in all treated patients, and a mean number of 2 of the 3 sutures persisted at 3 and 12 months of follow-up. These results are in line with the fact that the endomina platform allows performing full thickness plications [11]. Previous studies using endoscopic suturing devices in GERD patients showed that only transmural, full-thickness sutures do not fall out and persist with time [13, 14]. In our study, the loss of one third of the sutures after 3 months is probably due to the loss of lose or partial thickness plications.

Second, the study provides objective data suggesting the efficacy of the device for treating GERD. We observed an increase in basal and relaxation LES pressures as markers of LES augmentation after
suturing the EGJ junction, as well as a decrease in reflux parameters measured during ambulatory reflux monitoring, these changes should of course be confirmed in a study with a larger number of patients. In parallel, improvement of GERD symptoms was observed in most of the patients. Most of the patients followed at 12 months had no esophagitis and were able to reduce or stop their PPI usage. Due to the small number of patients included, it is not possible to evaluate if the clinical efficacy of the procedure was linked to the number of sutures remaining at the EGJ. Those results on objective reflux parameters and GERD symptoms should be confirmed in a study with a larger number of patients.

During the last decades, several endoscopic suturing devices were developed. EndoCinch suturing device allowed submucosal sutures that did not persist and therefore could not offer long term efficacy on GERD [14]. More recently, the transoral incisionless fundoplication (TIF) which has been the most evaluated device to date, the Medigus ultrasonic surgical endostapler (MUSE) and the GERDx procedure were evaluated in clinical trials with encouraging results [15, 16]. Some of these devices are however limited by their size making their use sometimes difficult in retroflexion [13].

The endomina platform has some advantages, such as ease of use, manoeuvrability, ability to attach/detach during the procedure, and atraumatic design (i.e., no need for an overtube). It can be used with all types of endoscopes without the need for specific materials. The design of the endomina v2-mini is smaller in diameter, with a piercing angle of 35 degrees, rendering the device able to work in retroflexion more efficiently in small spaces. Future studies should also evaluate where to place the sutures to offer the best results in augmenting the anti-reflux barrier.

The limitations of the study are inherent to a pilot study without randomization and a sham arm, with a small number of patients included, the COVID-19 pandemic occurring during the recruitment period. The majority of enrolled patients were men, which might be a bias. One could also argue that the inclusion criteria of GERD are not validated, the protocol of the study was written before the Lyon Consensus was published. Two patients missed their 3- or 6-months follow-up and 5 patients
were lost to follow-up. Among these patients, 2 patients opted later for a surgical fundoplication, and 
one can argue that patients lost to follow-up were not satisfied and had persisting GERD symptoms. 
Questions of the GERD-HRQL on regurgitations were not included in the Portuguese version of the 
questionnaires, limiting the number of available data for this tool. Finally, 1-year follow-up is short in 
a chronic condition like GERD, and long-term results cannot be guaranteed with this new endoscopic 
approach.

The strength of the study lies in its prospective design with precise inclusion and exclusion criteria, 
and that it was performed on two sites.

In conclusion, current data show that endoscopic full-thickness suturing of the EGJ with the 
endomina v2 device is a safe procedure, allowing long-term plications to augment LES, with 
encouraging results to decrease reflux and improve GERD symptoms. The procedure should be 
further evaluated in a larger prospective, to confirm its safety, the sustainability of the sutures and 
the effects on both objective GERD measurements and symptoms.
6. Figure legends and tables

**Figure 1**  (A) Esophagogastric junction seen in retroflexion. Black marker shows where the sutures will be placed. (B) After the placement, a thread can be seen between tags. (C) Illustration of the technique with the endomina v2 device in place. (D) Illustration of the final result. (E) Esophagogastric junction seen in retroflexion after 12 months after the procedure. Threads are still visible on the left and right part of the endoscope.

**Figure 2** Flow diagram of the study. In the right part of the diagram, n = total number of patients from Brussels and Lisbon, n in brackets = number of patients from Brussels.
Table 1 Baseline characteristics of study population (14 patients)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean ± SD</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>Mean ± SD 43 ± 12</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Female/Male (n) 1/13</td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>Mean ± SD 78.7 ± 16.1</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>Mean ± SD 25.6 ± 3.8</td>
<td></td>
</tr>
<tr>
<td>Heartburn GERD-HRQL (Q1-6) on/off PPI</td>
<td>Mean ± SD 15.3±7.4 /23.5±3.7</td>
<td></td>
</tr>
<tr>
<td>Regurgitation GERD-HRQL (Q10 to Q13) on/off PPI</td>
<td>Mean ± SD 11.2±2.4/13.9±3.0</td>
<td></td>
</tr>
<tr>
<td>Esophagitis (LA grade 0/A/B/C)</td>
<td>% Patients 14/50/22/14</td>
<td></td>
</tr>
<tr>
<td>PPI dose (half/single/double)</td>
<td>% Patients 22/50/28</td>
<td></td>
</tr>
<tr>
<td>pH-impedance monitoring results</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acid exposure time (%)</td>
<td>Median [IQR] 6.0 [3.5 – 9.5]</td>
<td></td>
</tr>
<tr>
<td>Number of reflux episodes</td>
<td>Median [IQR] 78 [62 – 96]</td>
<td></td>
</tr>
</tbody>
</table>

Heartburn and regurgitations GERD-HRQL scores were recorded on PPI medication and off PPI (7 days after PPI stopping). Regurgitation scores are data from patients treated in Brussels (n=8).
Table 2: Therapeutic outcomes of the study

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Intervention</th>
<th>3 months of follow-up</th>
<th>6 months of follow-up</th>
<th>12 months of follow-up</th>
<th>Median of delta (IC95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean number of stitches</td>
<td>3 ± 1</td>
<td>2 ± 1</td>
<td></td>
<td></td>
<td></td>
<td>-1.7 (-5.9; 7.8)</td>
</tr>
<tr>
<td>Acid exposure time (%)</td>
<td>6.0 [3.5 – 9.5]</td>
<td>2.6 [2.2 – 10]</td>
<td></td>
<td></td>
<td></td>
<td>-28 (-50; 29)</td>
</tr>
<tr>
<td>Number of reflux episodes</td>
<td>78 [62 – 96]</td>
<td>40 [37 – 66]</td>
<td></td>
<td></td>
<td></td>
<td>-14 (-36; 5)</td>
</tr>
<tr>
<td>Number of proximal reflux episodes</td>
<td>55 [46 – 61]</td>
<td>34 [26 – 46]</td>
<td></td>
<td></td>
<td></td>
<td>-42 (-83; 5)</td>
</tr>
<tr>
<td>DeMeester score</td>
<td>19.7 [16.2 – 29]</td>
<td>10.5 [7.3 – 29.7]</td>
<td></td>
<td></td>
<td></td>
<td>-7.3 (-22.6; 16.1)</td>
</tr>
<tr>
<td>Basal LES pressure (mmHg)</td>
<td>10 [8 – 19]</td>
<td>16 [10 – 19]</td>
<td></td>
<td></td>
<td></td>
<td>2 (-4; 10)</td>
</tr>
<tr>
<td>IRP4s</td>
<td>3.9 [1.0 – 5.8]</td>
<td>6.1 [4.0 – 8.1]</td>
<td></td>
<td></td>
<td></td>
<td>1.5 (-1.63; 3.5)</td>
</tr>
<tr>
<td>RSI</td>
<td>16.5 ± 9.1</td>
<td>6.7 ± 9.7</td>
<td>7.9 ± 8.2</td>
<td>6.1 ± 8.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GERD-HRQL (Q1 to Q9)</td>
<td>24.0 ± 7.4</td>
<td>8.0 ± 10.6</td>
<td>10.2 ± 13.9</td>
<td>6.3 ± 7.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regurgitation GERD-HRQL (Q10 to Q13)</td>
<td>14.1 ± 2.6</td>
<td>6.9 ± 6.7</td>
<td>8.5 ± 8.3</td>
<td>3.3 ± 2.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients under PPI (%)</td>
<td>14 (100)</td>
<td>5 (50)</td>
<td>1 (11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose of PPI (mg, min. – max.)</td>
<td>15 – 80</td>
<td>10 – 40</td>
<td>7.5 – 7.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>76 [72 – 90]</td>
<td>75 [68 – 84]</td>
<td>77 [68 – 80]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Regurgitation GERD-HRQL scores are data from patients treated in Brussels. Values followed by brackets indicate Median and interquartile range. Values followed by plus/minus indicate mean and standard deviation. pH-impedance results at baseline and at 6-months follow-up were obtained after 7 days off PPI.
7. References


Included patients
n=17 (11)

Enrollment failure
n=3
- 1 previous Nissen
- 1 Barrett's esophagus
- 1 gastroparesis

Treated patients
n=14 (8)

Missed 3 months follow-up
n=1

Follow-up 3 months
n=13 (8)

Lost of follow-up
n=3

Missed 6 months follow-up
n=1

Follow-up 6 months
n=10 (5)

Lost of follow-up
n=2

Follow-up 12 months
n=9 (3)